A landmark $16M clinical trial led by Sylvester Comprehensive Cancer Center will assess AI's impact on radiologist performance in mammography screening.
Key Details
- 1PRISM is the first major randomized U.S. trial to study AI in breast cancer screening.
- 2Supported by a $16 million award from PCORI, the study spans hundreds of thousands of mammograms across six states.
- 3Seven academic medical centers, including UCLA and University of Miami, are participating.
- 4The trial uses Transpara by ScreenPoint Medical as the AI tool, integrated via Aidoc aiOS.
- 5Radiologists will remain in control of interpretations, with randomized assignment to AI-assisted or radiologist-only reads.
- 6Outcomes include cancer detection, recall rates, and perceptions of AI from both patients and clinicians.
Why It Matters
This large, multicenter trial could establish high-level evidence on the true value of AI assistance in real-world breast imaging, directly influencing clinical implementation, policy, and practice. Its patient-centered design and rigorous methodology will help clarify how—and for whom—AI can best improve breast cancer screening results.
Source
EurekAlert
Related News
•EurekAlert
Dana-Farber Showcases AI and Clinical Trial Advances at ESMO 2025
Dana-Farber researchers present major cancer clinical trial results, including AI-driven data analysis, at ESMO Congress 2025.
•EurekAlert
Einstein College Awarded $18M NIH Grant to Develop AI Tools for Mental Health Crisis Prediction
Albert Einstein College of Medicine received an $18 million NIH grant to create AI-based tools for predicting mental health crises using cognitive monitoring.
•EurekAlert
Imaging Reveals Skull Changes and Immune Impact in Glioblastoma
Advanced imaging uncovers that glioblastoma affects the skull and immune system, not just the brain.